Discover more articles from Norgen

Meta Description: 
Scientifc Blog
By: Iva L.

Currently, there is limited technology available for accurately predicting high-risk cancer biochemical recurrence (BCR).

By: Michelle S.

A group of researchers from the Institute of Health Carlos III (ISCIII) in Spain, presented a poster at the annual meeting for the International Society of Extracellular Vesi

By: The Norgen Team

A recent study conducted by researchers at the Macquarie University in Sydney, Australia evaluated the efficiency of several commercially available kits for extracting cell-free circulating DNA from plasma samples.

By: The Norgen Team

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illum

By: The Norgen Team

On July 10th and 11th 2018Norgen Biotek Corp.

By: Ben M.

For Norgen Biotek Corp.’s CEO and president, Dr. Yousef Haj-Ahmad, 2018 marks a significant year in career as a leading mind in the biotechnology industry.

Pages